QBW251 is a type of CFTR Modulator called a “potentiator”. Similar to the drug ivacaftor, this drug would help to facilitate the opening of the chloride channel on the cell surface. This compound is administered through an oral pill.

Status

Phase 2a trials were completed in people with CF with residual function mutations. No further development in CF is planned at this time.

Sponsor

This program is sponsored by Novartis and was conducted within the Therapeutics Development Network.